Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy
暂无分享,去创建一个
A. Foli | P. Milani | G. Merlini | G. Palladini | M. Nuvolone | F. Lavatelli | F. Benigna | Lara Rodigari | Marco Basset
[1] E. Burks,et al. Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis. , 2020, Blood advances.
[2] D. Dingli,et al. Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis , 2020, Blood Cancer Journal.
[3] P. Hawkins,et al. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. , 2019, Blood.
[4] D. Dingli,et al. Revisiting complete response in light chain amyloidosis , 2019, Leukemia.
[5] C. Varga,et al. In Systemic Light-Chain Amyloidosis Complete and Very Good Partial Responses Are Not Enough: Involved Free Light Chain (iFLC) Levels < 10mg/L Are Associated with Optimal Long-Term Survival , 2019, Blood.
[6] K. Thoren,et al. MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins. , 2019, Clinica chimica acta; international journal of clinical chemistry.
[7] L. Ramanathan,et al. Distinguishing Drug from Disease by Use of the Hydrashift 2/4 Daratumumab Assay. , 2019, The journal of applied laboratory medicine.
[8] P. Milani,et al. What does minimal residual disease mean in AL amyloidosis? , 2018, Expert Opinion on Orphan Drugs.
[9] A. Dispenzieri,et al. Systemic immunoglobulin light chain amyloidosis , 2018, Nature Reviews Disease Primers.
[10] D. Dingli,et al. Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio , 2018, Leukemia.
[11] D. Dingli,et al. Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains , 2018, Leukemia.
[12] H. Goldschmidt,et al. AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis. , 2017, Blood.
[13] P. Milani,et al. The utility of MASS‐FIX to detect and monitor monoclonal proteins in the clinic , 2017, American journal of hematology.
[14] D. Dingli,et al. The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. , 2017, Blood.
[15] A. Foli,et al. Persistence of Minimal Residual Disease By Multiparameter Flow Cytometry Can Hinder Recovery of Organ Damage in Patients with AL Amyloidosis Otherwise in Complete Response , 2016 .
[16] T. Plesner,et al. Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference , 2016, Clinical chemistry and laboratory medicine.
[17] A. Foli,et al. Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome. , 2015, Blood.
[18] A. Foli,et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. , 2014, Blood.
[19] M. Dimopoulos,et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.